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Introduction: Homologous recombination repair (HRR) is a critical 
pathway for the repair of DNA damage caused by cisplatin or poly-
ADP ribose polymerase (PARP) inhibitors. HRR may be impaired 
by multiple mechanisms in cancer, which complicates assessing the 
functional HRR status in cells. Here, we monitored the ability of 
non–small-cell lung cancer (NSCLC) cells to form subnuclear foci 
of DNA repair proteins as a surrogate of HRR proficiency.
Methods: We assessed clonogenic survival of 16 NSCLC cell lines 
in response to cisplatin, mitomycin C (MMC), and the PARP inhibi-
tor olaparib. Thirteen tumor explants from patients with NSCLC 
were subjected to cisplatin ex vivo. Cells were assayed for foci of 
repair-associated proteins such as BRCA1, FANCD2, RAD51, and 
γ-H2AX.
Results: Four cell lines (25%) showed an impaired RAD51 foci-
forming ability in response to cisplatin. Impaired foci formation 
correlated with cellular sensitivity to cisplatin, MMC and olaparib. 
Foci responses complemented or superseded genomic information 
suggesting alterations in the ATM/ATR and FA/BRCA pathways. 
Because baseline foci in untreated cells did not predict drug sensi-
tivity, we adapted an ex vivo biomarker assay to monitor damage-
induced RAD51 foci in NSCLC explants from patients. Ex vivo 
cisplatin treatment of explants identified two tumors (15%) exhibit-
ing compromised RAD51 foci induction.
Conclusions: A fraction of NSCLC harbors HRR defects that may 
sensitize the affected tumors to DNA-damaging agents including 
PARP inhibitors. We propose that foci-based functional biomarker 
assays represent a powerful tool for prospective determination of 
treatment sensitivity, but will require ex vivo techniques for induc-
tion of DNA damage to unmask the underlying HRR defect.
Key Words: Lung cancer, Homologous recombination, RAD51, 
Biomarker.
(J Thorac Oncol. 2013;8: 279-286)
In patients with advanced or metastatic non–small-cell lung cancer (NSCLC) treated with platinum-based chemother-
apy regimens, disease response rates are only in the range of 
15 to 35%. Although overexpression of the nucleotide exci-
sion repair protein ERCC1 or presence of mutant K-RAS in 
NSCLC have been associated with resistance to platinum-
based chemotherapy,1 there is a paucity of biomarkers to 
predict which tumors are likely to be sensitive to platinum or 
targeted agents such as poly-ADP ribose polymerase (PARP) 
inhibitors.
Homologous recombination repair (HRR) is a pathway 
critical for several cellular processes including the error-
free repair of DNA double-strand breaks (DSB) and the 
recovery of stalled DNA replication forks.2 Deregulated HRR 
results in genomic instability that may cause or contribute 
to carcinogenesis. Importantly, such HRR-defective tumors 
may be more sensitive to DNA-damaging chemotherapeutics 
such as cisplatin or PARP inhibitors. HRR may be altered 
by genetic, epigenetic, or other mechanisms, making it 
challenging to assess the functional HRR status in a given 
tumor. In addition, even though altered expression of genes 
involved in HRR, such as BRCA1 or FANCD2, has been 
described in NSCLC, it is unknown whether this is associated 
with a functionally relevant HRR defect.3–5 Interestingly, 
7% of lung adenocarcinomas harbor mutations in the DNA 
damage response ATM kinase, which is involved in HRR and 
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multiple other DNA repair and checkpoint functions,6 but 
the functional consequences of this alteration remain to be 
established.
Significantly, the activity of HRR and other DNA dam-
age response/repair pathways is less dependent on protein 
expression levels than on the proper localization of these 
proteins to sites of damaged DNA, which ensures spatio-
temporal coordination and execution of repair.2 Accordingly, 
in response to DNA damage, several of these proteins form 
microscopically visible foci that accumulate in the nuclei of 
cells. In contrast, in undamaged cells, the frequency of these 
subnuclear foci is low. Thus, the ability of cells to form repair 
protein foci may be regarded as a functional biomarker of the 
integrity of the HRR network and associated sensitivity to 
cisplatin and other anticancer agents. The advantage of using 
these foci as biomarkers is that they can detect repair defects 
due to various mechanisms such as epigenetic events or gene 
mutations. Moreover, they potentially provide a global mea-
surement of network function without needing to know the 
identities of all the components.
Here, we sought to discover functionally relevant HRR 
defects by interrogating a panel of NSCLC cell lines and tissues 
for their ability to form DNA damage-induced foci of RAD51 
recombinase, which is the central effector of HRR in cells.2
PATIENTS AND METHODS
Cell Lines
Cell lines were selected from a published panel located 
in the Center for Molecular Therapeutics at Massachusetts 
General Hospital, except for A549, Calu-6, and NCI-H2087, 
which were purchased directly from American Type Culture 
Collection (Manassas, VA). Cell lines were obtained dur-
ing 2008–2010 and cultures passaged for less than 3 months 
after thawing a given frozen vial. In the Center for Molecular 
Therapeutics, the identity of each of the cell lines in the panel 
was tested using a set of 16 short tandem repeats (AmpFLSTR 
Identifier KIT; Applied Biosystems, Bedford, MA). In addition, 
single-nucleotide polymorphism profiles based on a panel of 63 
single-nucleotide polymorphisms assayed using the Sequenom 
Genetic Analyzer (Sequenom, San Diego, CA) was used for in-
house identity checking whenever a cell line was propagated 
and confirmed uniqueness of cell lines for the ones without 
available short tandem repeats. A549 cells were maintained in 
Dulbecco’s modified Eagle medium, Calu-6 in α-MEM, ABC1, 
and NCI-H2126 in DMEM/F12, and HCC44, LU99B, NCI-
H1299, NCI-H1563, NCI-H1703, NCI-H1792, NCI-H1915, 
NCI-H2087, and NCI-H23 in NCI-H3122 in RPMI1640 (from 
Sigma-Aldrich, St. Louis, MO). SV40-transformed human 
fibroblasts, ATM-mutant AT5BIVA (GM5849A) and ATM 
wild-type NF (GM00637F), were provided by Simon Powell. 
Cells were grown in Dulbecco’s modified Eagle medium. 
Maintenance of PD20 with or without expression of wild-type 
FANCD2 has been described.7 All cell lines were maintained 
in a humidified incubator at 37°C and 5% CO
2
. All media 
was supplemented with 10% bovine growth serum (HyClone; 
Fisher Scientific, Hampton, NH), 20 mM HEPES, 2 mM L-glu-
tamine, 100 units/ml penicillin, and 100 µg/ml stretopmycin (all 
Sigma-Aldrich). No cell line was ever treated for mycoplasma 
and all lines were tested mycoplasma-free before the experi-
ments (MycoAlert; Lonza, Basel, Switzerland).
Tumor Tissues
Tumor tissues were obtained from previously untreated 
patients undergoing surgical resection for clinical stage I 
NSCLC under a protocol approved by the Boston University 
Medical School and Partners Institutional Review Boards. 
Tumor samples were processed for ex vivo foci analysis 
adapting a previously published protocol for breast cancer.8 
Under this protocol, tumor tissues not needed for pathologi-
cal diagnosis were placed into RPMI medium typically within 
30 minutes of surgical resection and arrived in the laboratory 
30 to 60 minutes later. Specimens were evenly divided into 
samples of less than 5 mm size depending on the amount of 
tissue available. Samples were mock treated or exposed to 10 
Gy radiation, followed by 5 hours incubation at 37°C and 5% 
carbon dioxide, and snap freezing, as described.8 In addition 
to the published protocol, one to two tumor samples were also 
exposed to cisplatin at 8 µM for 5 hours.
Treatment and Clonogenic Survival Assay
Treatments with cisplatin, mitomycin C, or ionizing 
radiation were carried out as described.7,9,10 Olaparib (LC 
Laboratories, Woburn, MA and AstraZeneca, Wilmington, 
DE) was dissolved in DMSO for a 20 mM stock solution and 
stored in aliquots at −20°C. Clonogenic cell survival was 
assessed as described.10
Immunofluorescence Microscopy
Exponentially growing cells were plated into eight-well 
chamber slides and treated with 8 µM cisplatin as described 
previously.10 Visualization of RAD51, FANCD2, and γ-H2AX 
foci in cell lines was performed as described.10,11 For BRCA1, 
cells were incubated with an anti-BRCA1 mouse monoclonal 
antibody (OP92, Calbiochem; EMD Millipore Corporation, 
Billerica, MA) at a 1:200 dilution. For RAD51 and proliferat-
ing cell nuclear antigen (PCNA) costaining, PD20 cells were 
permeabilized first with 0.5% Triton X, 20 mM HEPES, 50 mM 
NaCl, 3 mM KCl, and 300 mM sucrose on ice for 5 minutes, 
followed by fixation with 2% paraformaldehyde at room tem-
perature for 20 minutes and 100% methanol at −20°C for 10 
minutes. Cells were exposed to primary antibodies against 
PCNA (rabbit polyclonal ab2426; Abcam, Boston MA) and 
RAD51 (mouse monoclonal ab213, Abcam) both at 1:200 dilu-
tion in 2% bovine serum albumin, 0.1% Triton X-100, followed 
by incubation with secondary antibodies (Alexa Fluor-488 goat 
antimouse, Invitrogen A11029, and Alexa Fluor-568 goat anti-
rabbit, Invitrogen A11011) at 1:1000 dilution and 4′,6-diamid-
ino-2-phenylindole counterstaining. Phospho-ATM foci were 
visualized with anti-phospho-ATM (serine1981) mouse mono-
clonal antibody (200-301-400; Rockland, Gilbertsville, PA). 
Costaining with PCNA was performed as described earlier. For 
costaining with 53BP1 foci, an anti-53BP1 rabbit polyclonal 
antibody (Abcam) was used. For all experiments, the number 
of foci per nucleus was determined by analyzing 100 to 300 
nuclei per data point. For quantification of “induced foci,” the 
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number of foci per nucleus in untreated cells was subtracted 
from the foci number in treated cells and appropriate cutoffs 
between 10 and 20 foci per nucleus were chosen to determine 
the fraction of cells positive for foci formation depending on 
the particular endpoint. Observers were generally blinded as to 
whether cells had been treated.
Detection of RAD51 foci in tumor tissues has been 
described.8 For visualization of γ-H2AX, cryosections were 
fixed with 2% paraformaldehyde for 15 minutes, permeabilized 
with 0.5% Triton X-100 for 5 minutes at room temperature, and 
stained with anti-γ-H2AX (phospho-S139) mouse monoclonal 
antibody (ab18311; Abcam) at 1:500 dilution at 4°C overnight, 
which was followed by incubation with secondary antimouse 
Alexa Fluor-488 antibody (Invitrogen, Carlsbad, CA) at 1:1000 
dilution for 1 hour at room temperature. For PCNA staining, 
tissue sections were permeabilized first with 0.1% Tween-20 
for 10 minutes and incubated with anti-PCNA rabbit polyclonal 
antibody (#ab2426; Abcam) at 1:200 dilution. For foci quantifi-
cation, typically seven to 10 random images per data point were 
captured and 200 to 400 nuclei scored. Nuclei with at least two 
foci were considered positive. For three-dimensional rendering 
(Fig. 4C), a Z-series of images was taken for each treatment 
(SlideBook 5.0, IX81 Olympus confocal microscope; Olympus 
America Inc., Chelmsford, MA). The step size was 0.1 µm, and 
the number of planes was 40. The Z-series was deconvolved 
using the Constrained Iterative Method. The deconvolved 
Z-series was assembled into three-dimensional images using 
the three-dimensional Volume view option in SlideBook.
RESULTS
A NSCLC Cell Line Screen Reveals 
Putative HRR Defects
To identify NSCLC cell lines with impaired HRR, 
we sought to screen for the ability of cisplatin-treated cells 
to form subnuclear foci of RAD51, an established surro-
gate marker of HRR activity.12,13 We first established that 
human cells with a known defect in the HRR pathway 
exhibit impaired RAD51 foci formation in the S-phase of 
the cell cycle, which is thought to reflect defective repair of 
replication forks that collide with drug-induced interstrand 
crosslinks.2 Impaired RAD51 formation was not only seen 
in S-phase cells, but was also detectable in asynchronously 
growing cell populations at both 5 and 24 hours after start 
of drug treatment (p < 0.05) (Fig. 1A, Supplementary Fig. 1, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A384). Next, we screened a panel of 16 NSCLC cell lines for 
their proficiency to form RAD51 foci in response to cisplatin 
treatment. There was a range of foci-forming ability, with 4 
of 16 cell lines (25%) demonstrating induced foci in 10% or 
less of cells suggesting a putative HRR defect (Fig. 1B). Cell 
cycle analysis indicated that the reduction in RAD51 foci 
formation was not due to a lower fraction of cells in S-phase 
(Supplementary Fig. 2, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A384).
RAD51 Foci Defect Correlates with 
Crosslinker and PARP Inhibitor Sensitivity
HRR-defective cells are expected to be sensitive to 
crosslinking agents, such as cisplatin or mitomycin C (MMC), 
but also PARP inhibitors.14 We first determined the cisplatin 
sensitivity of our cell line panel in a colony formation assay. 
Two RAD51 foci-impaired cell lines, H1915 and H2087, 
clearly demonstrated drug hypersensitivity (Fig. 2A), whereas 
the other two cell lines, H1563 and H2126, appeared to be 
relatively resistant to cisplatin. However, tumor cells could 
have acquired cisplatin resistance by other processes such as 
drug efflux mechanisms. We, therefore, also determined the 
MMC sensitivity of the four RAD51 foci-deficient cell lines 
FIGURE 1.  Monitoring the formation of subnuclear 
RAD51 foci in response to cisplatin treatment. (A) 
FANCD2-mutant (mut) PD20 fibroblasts with or 
without exogenous expression of wild-type (wt) 
FANCD2 were exposed to cisplatin (8 µM) for 1 
hour and subjected to immunofluorescence stain-
ing for the S-phase marker nuclear PCNA and 
RAD51 recombinase at 5 and 24 hours (h). Left 
panel shows representative images of costaining for 
PCNA (red) and RAD51 (green), in conjunction with 
4′,6-diamidino-2-phenylindole (blue) counterstain-
ing. Right panel shows fraction of cells with induced 
RAD51 foci in PCNA-positive S-phase cells or all 
cells. Bars represent mean with standard error based 
on three independent repeat experiments. Arrow 
indicates representative nucleus with intact RAD51 
foci formation in an S-phase cell. *p < 0.05 (t test, 
two-tailed). (B) Analogous to panel A, 16 NSCLC 
cell lines were exposed to cisplatin and screened for 
induced RAD51 foci at 5 hours. Bars represent the 
fraction of cells with at least 15 induced RAD51 foci. 
NSCLC, non–small-cell lung cancer; PCNA, prolifer-
ating cell nuclear antigen.
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and detected reduced clonogenic survival in all these cell lines 
compared with a set of RAD51 foci-proficient cell lines (Fig. 
2B). Inhibition of PARP is known to cause synthetic lethality 
in HRR-deficient BRCA mutant cells.2 Consistent with this, 
three of the RAD51 foci-deficient cell lines demonstrated 
increased sensitivity to olaparib (Fig. 2C). It remained unclear 
why H2126 cells are resistant to olaparib, though it is possible 
that the very slow growth of this cell line may have reduced 
the number of drug-induced breaks encountered during a cell 
cycle.
Interestingly, one seemingly RAD51-proficient cell line, 
Calu-6, was sensitive to cisplatin and olaparib (Fig. 2A and 
2C). Because there could be a defect parallel to or downstream 
of RAD51 foci formation, we also assessed the levels of resid-
ual γ-H2AX foci as a marker of DSB.15 After cisplatin treat-
ment, we found high levels of DSB in Calu-6 cells, pointing 
toward an underlying recombinational repair defect (Fig. 2D). 
For all cell lines, there was an excellent correlation between 
the levels of residual DSB and cisplatin sensitivity (Fig. 2D). 
Thus, both RAD51 and γ-H2AX foci may be used to identify 
functionally relevant recombinational repair defects that are 
associated with cisplatin sensitivity.
ERCC1 is also involved in the repair and restart of repli-
cation forks, and is used as a biomarker of cisplatin resistance 
in the clinic.1 We did not find a correlation between RAD51 
foci induction and ERCC1 gene expression, suggesting that 
ERCC1 is not a surrogate for RAD51 (Supplementary Fig. 3, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A384).
Multiple Mechanisms Underlying 
Crosslinker Sensitivity in NSCLC Cells
Of the four cell lines with impaired RAD51 function, 
one cell line, H2126, has a genomic alteration in a pathway 
known to control HRR in response to replication stress,16 i.e., a 
heterozygous mutation in the ATR kinase. H2087 cells harbor 
a mutation in the ATM kinase impairing phosphorylation 
at the S1981 site (Supplementary Fig. 4A, Supplemental 
FIGURE 2.  Sensitivity of NSCLC cell lines to DNA-damaging anticancer drugs. (A) Left panel shows representative examples 
of colony forming ability after treating A549 cells (200 cells seeded) or cisplatin-sensitive cell lines (2000–5000) with 16 µM 
cisplatin. Right panel, clonogenic survival fraction is plotted against cisplatin concentration. Data points represent mean with 
standard error based on at least two independent repeat experiments. Cell lines with putative RAD51 foci formation defects 
are highlighted in red. (B) Clonogenic survival fraction after treatment with 0.25 mg/ml mitomycin C for 1 hour is plotted for a 
subset of cell lines. (C) Clonogenic survival fraction after treatment with 10 µM of olaparib for 72 hours. Cell lines with putative 
RAD51 foci formation defects are highlighted in red. Bars represent mean with standard error based on at least two indepen-
dent repeat experiments. (D) Left panels illustrate the difference in the formation of γ-H2AX foci at 24 hours after treatment 
of cisplatin-resistant H1703 and cisplatin-sensitive Calu-6 cells with 8 µM cisplatin. Right panel shows the correlation between 
clonogenic cell survival versus residual γ-H2AX foci present at 24 hours after cisplatin treatment with 8 µM. Dotted line reflects 
95% confidence limits of the linear regression line. NSCLC, non–small-cell lung cancer.
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Digital Content 1, http://links.lww.com/JTO/A384). ATM 
is known to be involved in nonhomologous end-joining and 
HRR after the induction of DSB by ionizing radiation but 
has not been previously implicated in cisplatin resistance.17 
Follow-up analysis in several cell systems established that 
ATM is required for cellular cisplatin resistance (Fig. 3A, 
Supplementary Fig. 4B, Supplemental Digital Content 1, http://
links.lww.com/JTO/A384). The kinetics of ATM activation 
followed the time course of DSB induction (Supplementary 
Fig. 4C, Supplemental Digital Content 1, http://links.lww.
com/JTO/A384). Phosphorylated ATM co-localized with DSB 
(Fig. 3B), was detected during DNA replication within 6 hours 
after cisplatin treatment (Fig. 3B, Supplementary Fig. 4D, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A384), and formed in a manner that appeared at least partially 
dependent on ATR (data not shown), consistent with a role of 
ATM at stalled replication forks.18
For RAD51 foci-impaired cell lines H1563 and H1915, 
no preexisting genomic alteration in a putative HRR pathway 
was known. We thus screened for reduced expression of com-
ponents of the FA/BRCA pathway and detected decreased 
FANCD2 and BRCA1 expression, respectively (data not 
shown), consistent with previous reports showing altered 
expression of these genes in lung cancer.3,4 Significantly, we 
found a reduced ability to form FANCD2 foci in both cell 
lines (Fig. 3C). In addition, in H1915 cells, there was reduced 
foci formation of BRCA1 (Fig. 3D), which is upstream of 
FANCD2 foci formation.19
Unexpectedly, our analysis also revealed that H1299 
cells exhibit reduced expression of FANCF (Supplementary 
Fig. 5A, Supplemental Digital Content 1, http://links.lww.com/
JTO/A384), which was associated with impaired FANCD2 
foci formation (Fig. 3C) and mono-ubiquitination of FANCD2 
(Supplementary Fig. 5B, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A384). However, these cells were 
not crosslinker sensitive (Fig. 2A and 2B), likely due to unusu-
ally high levels of RAD51 protein (Supplementary Fig. 5C, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A384) that may act in a compensatory manner.20,21
An Ex Vivo Biomarker Assay to 
Monitor the Effects of Anticancer 
Agents in Live Tumor Explants
Our cell line work indicated that chemosensitiv-
ity is correlated with an impaired ability to induce RAD51 
FIGURE 3.  Pathway correlates of cisplatin sensitivity. (A) Clonogenic survival of human fibroblasts with wild-type (wt) or 
mutant (mut) ATM treated with varying doses of cisplatin for 1 hour. Data points represent mean with standard error based 
on three independent repeat experiments. (B) Representative images demonstrating colocalization of phospho-ATM foci with 
53BP1 or PCNA at 24 hours after cisplatin treatment of A549 cells. (C) Analysis of FANCD2 foci formation at 5 hours in a subset 
of cell lines treated with 8 µM cisplatin. Bars represent the fraction of cells with 20 or more foci per nucleus. (D) Representative 
images illustrating the reduced ability of H1915 cells to form BRCA1 foci in response to cisplatin. PCNA, proliferating cell 
nuclear antigen.
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foci after drug treatment (Fig. 1, Supplementary Fig. 6A, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A384), but not with the baseline number of foci in untreated 
cells (Supplementary Fig. 6A, Supplemental Digital Content 
1, http://links.lww.com/JTO/A384). Thus, assaying RAD51 
foci on archived tumor samples (from pretreatment biopsies) 
was not expected to be informative.
We, therefore, adapted an ex vivo biomarker assay pre-
viously tested in breast cancer to determine if impaired HRR 
activity can be detected in NSCLC.8 Fresh tumor tissues from 
patients with untreated NSCLC were collected and within 90 
minutes of removal from the patient exposed to cisplatin or 
radiation in the laboratory (Fig. 4A). Tissues were incubated 
in parallel for 5 hours before snap freezing. Serial cryosec-
tions were analyzed for viable tumor by H&E staining and 
nuclear protein foci using immunofluorescence microscopy 
(Fig. 4B). Damage-induced γ-H2AX foci were readily visu-
alized after irradiation or cisplatin treatment (Fig. 4B and 
4C, Supplementary Fig. 6B, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A384).
We assessed a total of 13 NSCLC explants for cellular 
proficiency to form RAD51 foci in response to cisplatin 
treatment (Fig. 5A). Similar to the cell line data, there was a 
range of foci induction with levels overall lower than in cell 
lines, i.e., on average, only 5.8% of tumor cells (95% CL, 
3.0–8.7%) exhibited RAD51 foci. In 2 of 13 tumors (15%), 
i.e., explants L006 and L007, very few RAD51 foci (in <1% 
of cells) were seen in the cisplatin-treated specimens, which is 
indicative of impaired HRR activity. The overall lower fraction 
of cells with RAD51 foci in explants compared with the cell 
lines was explained by a several fold fraction of cells in S-phase 
(Fig. 5B, Supplementary Fig. 6C, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A384). Importantly, 
tumors with putative HRR defects displayed an S-phase 
fraction comparable with RAD51 foci-proficient tumors, as 
illustrated in Figure 5C. In addition, low RAD51 foci levels 
did not result from a lack of DNA damage induction, as shown 
by the ability of cisplatin to generate γ-H2AX foci in these 
explants (Fig. 5D, Supplementary Fig. 6B, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A384). Taken 
together, these data demonstrate the feasibility of monitoring 
a drug-induced cellular DNA damage response in live tumor 
explants ex vivo.
DISCUSSION
The identification of HRR-deficient tumors is a major 
challenge in cancer research, in particular when taking into 
account the complexity of the DNA damage response net-
work.2 In addition, assessing the expression of individual net-
work components is unlikely to reveal the overall incidence of 
defects that can occur anywhere in the network. Finally, it is 
not established whether reduced expression of genes involved 
in HRR translates into functional repair impairment.
There has been increasing interest in determining HRR 
activities in cancers by assaying for the subnuclear location of 
central pathway components, such as RAD51, BRCA1, and 
FANCD2, and unrepaired DSB marked by γ-H2AX.8,22,23 The 
advantage of using foci as biomarkers is that they can capture 
repair defects due to various mechanisms such as gene mutations, 
epigenetic changes, or alterations in signal transduction 
pathways.2 Moreover, they provide a global measurement of 
network function without needing to know the identities of all 
the components, many of which remain unknown.
Here, we report for the first time the presence of 
impaired RAD51 foci formation in 4 of 16 NSCLC cell lines 
(25%). All four cell lines were MMC hypersensitive (Fig. 2B), 
whereas the sensitivity profile for cisplatin and olaparib was 
more heterogeneous (Fig. 2A and 2C). Although the exact 
reason for this differential effect remains to be elucidated, it is 
conceivable that residual HRR function in some cell lines is 
sufficient to cope with the consequences of intrastrand DNA 
damage associated with olaparib and/or cisplatin treatment. In 
contrast, a higher percentage of the DNA damage generated 
by MMC consists of damage affecting both DNA strands, i.e., 
FIGURE 4.  Ex vivo foci assay in NSCLC explants. (A) Surgical specimens from untreated patients were incubated under stan-
dard cell culture conditions and exposed to 8 µM cisplatin, 10 Gy radiation, or mock treatment ex vivo. Specimens were snap 
frozen after 5 or 24 hours and subjected to cryosectioning at a later time. (B) Serial cryoslides were analyzed by H&E staining to 
identify viable tumor and immunofluorescence (IF) microscopy to visualize repair protein foci. (C) Three-dimensional rendering 
of tissue nuclei counterstained with γ-H2AX 5 hours after mock treatment or irradiation ex vivo. NSCLC, non–small-cell lung 
cancer.
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interstrand crosslinks, which places a much greater burden on 
the cellular DNA repair response than the damage resulting 
from the other two compounds.2 Thus, assaying for tumors 
with defective RAD51 formation should at least enrich for 
those that may respond to cisplatin or PARP inhibitors.
In addition, we detected a strong correlation between 
persisting γ-H2AX foci and cisplatin sensitivity. These data 
and the identification of one RAD51-proficient cell line, Calu-
6, which demonstrates high γ-H2AX levels and cisplatin sen-
sitivity, support the notion that joint assessment of RAD51 
and γ-H2AX foci may be sufficient to reliably identify plati-
num- and perhaps also olaparib-sensitive tumors. Importantly, 
RAD51 foci form independently of ERCC1,24 and we do not 
find a correlation between foci induction and ERCC1 expres-
sion (Supplementary Fig. 3, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A384). Whether ERCC1 in con-
junction with RAD51 and γ-H2AX foci constitutes a useful 
biomarker set requires further study.
Our data indicate that foci responses yield information 
that can complement or supersede genomic information. For 
example, ATM-mutant H2087 cells were sensitive to cispla-
tin and displayed impaired RAD51 foci (Fig. 3), even though 
ATM has not been previously implicated in cellular cisplatin 
resistance. As a fraction of lung adenocarcinoma (7%) har-
bor nonrecurrent mutations throughout the ATM gene,6 the 
assessment of foci responses in these tumors may provide 
information on the functional significance of these alterations. 
As another example, FANCF hypermethylation was reported in 
14% of NSCLC, but the functional impact of these epigenetic 
events has remained unknown.4 Here, we found that the often 
studied H1299 cell line displays suppressed FANCF expres-
sion and impaired downstream FANCD2 function (Fig. 3, 
Supplementary Fig. 5, Supplemental Digital Content 1, http://
links.lww.com/JTO/A384), yet retains RAD51 function and 
drug resistance (Fig. 2), which highlights the usefulness of 
RAD51 and γ-H2AX foci as biomarkers of functionally rel-
evant repair defects and drug sensitivity.
How can foci assays in cell lines be translated into 
patients? It is important to appreciate that the functional status 
of HRR is typically revealed only when cells are exposed 
to DNA damage.8 Assessing foci responses in live tumors 
would require a repeat biopsy after initial administration of 
treatment, which is a challenging undertaking. Alternatively, 
pretreatment biopsies can be interrogated for their functional 
HRR status to select the appropriate treatment regimen for a 
given patient (Fig. 4A). We report here for the first time that 
cisplatin induces a damage response in NSCLC explants 
from untreated patients (Fig. 5D, Supplementary Fig. 6B, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A384). At least two of 13 tumors analyzed in this fashion 
demonstrated low RAD51 foci levels consistent with a 
functional HRR defect (Fig. 5A). Whether patients with these 
FIGURE 5.  Detection of cisplatin-induced RAD51 foci in live NSCLC explants. (A) Upper panel shows representative images 
demonstrating subnuclear RAD51 foci after 5 hour incubation after cisplatin. Lower panel displays the fraction of nuclei with 
RAD51 foci in a panel of 13 tumor explants. Bars represent mean with standard error. (B) Illustration of S-phase fraction in 
representative tumor tissue versus A549 cells using PCNA/DAPI counterstaining (see also Supplementary Fig. 6C, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A384). (C) Illustration of PCNA-positive S-phase fraction in RAD51 foci-proficient 
versus -deficient tumors. (D) Quantification of fraction of cells with cisplatin-induced γ-H2AX foci at 5 hours. Bars represent 
average fraction of nuclei with at least two foci ± standard error based on 8 to 10 random images and 200 to 400 nuclei per 
data point. DAPI, 4′,6-diamidino-2-phenylindole; NSCLC, non–small-cell lung cancer; PCNA, proliferating cell nuclear antigen.
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tumors indeed derive benefit from treatment with cisplatin or 
a PARP inhibitor remains to be determined.
Although this type of functional ex vivo foci assay rep-
resents a potentially powerful tool for the detection of pre-
existing and clinically relevant defects within the complex 
HRR pathway, several technical challenges remain, including 
(1) potential intratumoral heterogeneity in foci responses, (2) 
low fraction of cells in S-phase, compared with the cell lines, 
necessitating costaining techniques to detect replication-asso-
ciated RAD51 foci, (3) need for quantification and automation 
of foci scoring, and (4) potential changes in hypoxia/reoxy-
genation upon removal of the tumor tissue from the patient 
and incubation in the laboratory at 20% oxygen. Data from 
our laboratory and by Vaira et al.25 indicate that adequately 
cultured tumor explants are viable for at least 24 hours and up 
to 5 days, offering a promising avenue for assessing not only 
foci responses but also surrogate endpoints of cell fate such as 
apoptosis or senescence, thereby allowing pharmacodynamic 
profiling of human tumors.
In conclusion, it should be possible to use the ability of 
cells to form repair foci as a functional biomarker of the integ-
rity of the HRR pathway. The absence of repair foci induction, 
coupled with a persistence of DSB markers such as γ-H2AX, 
would be indicative of chemosensitivity or PARP inhibitor 
sensitivity. One can envision developing mechanism-based 
“HRR foci signatures” that reflect nodal points in the HRR 
pathway or network of associated DDR proteins. Such a foci 
signature likely will include at a minimum BRCA1, FANCD2, 
RAD51, and γ-H2AX to capture the multiple deficiencies that 
seem to underlie crosslinker and PARP inhibitor sensitivity in 
NSCLC.
Alterations in HRR in tumors can be therapeutically 
targeted by novel approaches such as PARP inhibitors and tra-
ditional DNA-damaging chemotherapeutics or radiation. The 
efforts to exploit preexisting HRR defects or disrupt proficient 
or hyperactive HRR in malignancies are in their infancy, but 
hold great promise to broadly impact cancer therapies in the 
very near future.2 As our understanding of the regulation of 
HRR pathways in normal and malignant cells deepens, vari-
ous rational treatment strategies are likely to materialize.26
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